Clinical Trial Update: Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy [Phase 2]

View source ↗

Summary

Phase 2 open-label study of KD025 in psoriasis vulgaris patients who failed first-line therapy has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• KD025

Snippet

Sponsor: Kadmon Corporation, LLC | Conditions: Psoriasis Vulgaris | Phase 2 | Status: COMPLETED | Results posted: 2021-11-01